Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL28237426 | 0.98 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1GAAMAPT | |
| Ethylene SCHEMBL27884218 | 0.95 | FFAR1 (0.56) | FFAR1FFAR4ALDH1A1GAAMAPT | |
| SCHEMBL3601077 | 0.93 | RARB (0.56) | FFAR1FFAR4ALDH1A1GAAMAPT | |
| SCHEMBL1430472 | 0.93 | ALDH1A1 (0.59) | FFAR1FFAR4ALDH1A1GAAMAPT | |
| SCHEMBL8990715 | 0.91 | RARB (0.55) | FFAR1FFAR4ALDH1A1GAAMAPT | |
| SCHEMBL13564082 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL2615718 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL3941872 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL2615717 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL9717309 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | claimed |
| EP-4276089-A2 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | Universite De Moncton (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| WO-1996010003-A1 | PROCESSES FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTYLAMINE AND ALKALI METAL SALTS OF DIFORMYLAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| EP-0673368-A1 | NOVEL NICOTINIC ACID ESTERS | Pharmacia & Upjohn Aktiebolag (SE) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994000434-A1 | NOVEL NICOTINIC ACID ESTERS | KABI PHARMACIA AB (SE) | 1994-01-06 | — | — | WO | disclosed |
| US-5189161-A | Analgesics | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | disclosed |
| US-5015738-A | Analgesics | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0412470-A2 | Benzo[b]pyrrolo[3,2,1-jk]benzodiazepines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-02-13 | — | — | EP | disclosed |
| EP-0308476-A1 | BISPHENYLALKYLPIPERAZINE DERIVATIVES, A METHOD OF THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION. | LEO AB (SE) | 1989-03-29 | — | — | EP | disclosed |
| WO-1988007528-A1 | BISPHENYLALKYLPIPERAZINE DERIVATIVES, A METHOD OF THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION | AKTIEBOLAGET LEO (SE) | 1988-10-06 | — | — | WO | disclosed |
| EP-0079564-A1 | 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles, a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-05-25 | — | — | EP | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | FFAR1 3512/4885FFAR4 3800/4885ALDH1A1 3448/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | FFAR1 3008/4885FFAR4 4318/4885ALDH1A1 569/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | FFAR1 3008/4885FFAR4 4318/4885ALDH1A1 569/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | FFAR1 3092/4885FFAR4 4410/4885ALDH1A1 1303/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | FFAR1 3008/4885FFAR4 4318/4885ALDH1A1 569/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | FFAR1 4682/4885FFAR4 4725/4885ALDH1A1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.